CYP2D6 inhibitors, such as SSRI medications, may increase plasma levels of risperidone and those medications. Since risperidone can cause hypotension, its use should be monitored closely when a patient is also taking antihypertensive medicines to avoid severe low blood pressure. Risperidone and its metabolite paliperidone are reduced in efficacy by P-glycoprotein inducers such as St Johns wort

Discontinuation
The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse. Some have argued the additional somatic and psychiatric symptoms associated with dopaminergic super-sensitivity, including dyskinesia and acute psychosis, are common features of withdrawal in individuals treated with neuroleptics. This has led some to suggest the withdrawal process might itself be schizomimetic, producing schizophrenia-like symptoms even in previously healthy patients, indicating a possible pharmacological origin of mental illness in a yet unknown percentage of patients currently and previously treated with antipsychotics. This question is unresolved, and remains a highly controversial issue among professionals in the medical and mental health communities, as well as the public. Dementia
Older people with dementia-related psychosis are at a higher risk of death. Pharmacology
Pharmacodynamics
Risperidone has been classified as a "qualitatively atypical" antipsychotic agent with a relatively low incidence of extrapyramidal side effects (when given at low doses) that has more pronounced serotonin antagonism than dopamine antagonism. Risperidone contains the functional groups of benzisoxazole and piperidine as part of its molecular structure. Although not a butyrophenone, it was developed with the structures of benperidol and ketanserin as a basis. It has actions at several 5-HT (serotonin) receptor subtypes.
The specific rotation is 
  
    
      
        [
        α
        
          ]
          
            D
          
          
            20
          
        
      
    
    {\displaystyle [\alpha ]_{D}^{20}}
   +65° to +72° cm³/dm·g (1% in dimethylformamide). Society and culture
In 2010, TEVA and Perrigo launched the first generic inhalable triamcinolone.According to Chang et al. (2014), "Triamcinolone acetonide (TA) is classified as an S9 glucocorticoid in the 2014 Prohibited List published by the World Anti-Doping Agency, which caused it to be prohibited in international athletic competition when administered orally, intravenously, intramuscularly or rectally". See also
Glucocorticoid (a chart comparing various glucocorticoids)
Triamcinolone acetonide (a derived and stronger drug)

References
External links
"Triamcinolone". Drug Information Portal. U.S. National Library of Medicine. "Triamcinolone Topical". MedlinePlus. "Triamcinolone Nasal Spray". MedlinePlus. "Triamcinolone Acetonide Cream". HealthClubFinder. 4 January 2021.